Autopsy report · NCT03722680

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

“Lack of treatment, sponsor decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 1 month before it started.
• Suspended: paused, and may or may not restart.
• 80 participants enrolled.

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

UNICANCER

Sponsor type

University, hospital or other

Conditions

Oxaliplatin-induced Peripheral Neuropathy

Interventions

Riluzole; Placebo Oral Tablet

Participants

80

Sites

16

Countries

France

Trials that died the same way

• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
  “Sponsor decision due to lack of enrollment.” (76% match in meaning)
• Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
  “Lack of additional funding; patients (3) no longer receiving intervention.” (74% match in meaning)
• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
  “Due to poor patient recruitment and insufficient financing.” (72% match in meaning)
• Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
  “Lack of funding support.” (72% match in meaning)
• The Effect of Theraworx Foam in Carpal Tunnel Syndrome
  “Lack of Funding from Sponsor” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.